for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innovent Biologics Inc

1801.HK

Latest Trade

41.65HKD

Change

0.30(+0.73%)

Volume

5,710,200

Today's Range

39.65

 - 

42.95

52 Week Range

37.10

 - 

105.00

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Innovent Says HK Health Dept. Approved Pemazyre To Treat Adults With Cholangiocarcinoma

Jan 24 (Reuters) - Innovent Biologics Inc <1801.HK>::HK HEALTH DEPARTMENT APPROVED PEMAZYRE TO TREAT ADULTS WITH LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH FGFR2 FUSION OR REARRANGEMENT.Further company coverage: 1801.HK. ((Reuters.Briefs@thomsonreuters.com;)).

Temasek Holdings' Long Position In Innovent Biologics Rises To 8.02% - HKEX Filing

Jan 10 (Reuters) - Hong Kong stock exchange filing::TEMASEK HOLDINGS (PRIVATE) LIMITED'S LONG POSITION IN INNOVENT BIOLOGICS INC <<<1801.HK>>> RISES TO 8.02% ON JAN 5 FROM 7.98% - HKEX FILING.

Innovent Biologics Notes Unusual Price And Trading Volume Movements Of Shares

Jan 5 (Reuters) - Innovent Biologics Inc <1801.HK>::NOTED UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS OF SHARES.CONFIRMS THAT ITS BUSINESS AND OPERATION REMAIN UNCHANGED.ACCELERATING ITS TRANSFORMATION FROM A BIOTECH CO TO A GLOBAL BIOPHARMACEUTICAL CO.AS OF DATE, HAS BUILT A PIPELINE OF 26 VALUABLE ASSETS & MORE THAN 80 PRECLINICAL PROJECTS.WILL CONTINUOUSLY EXPAND SALES VOLUME AND REVENUE OF OTHER COMMERCIAL PRODUCTS.WILL HAVE OVER 10 DRUGS TO BE LAUNCHED IN ITS COMMERCIALIZED PORTFOLIO WITHIN NEXT 2 YEARS.Further company coverage: 1801.HK. (Reuters.Briefs@thomsonreuters.com).

Innovent Biologics Says Nmpa Accepted Supplemental New Drug Application

Dec 24 (Reuters) - Innovent Biologics Inc <1801.HK>::NMPA ACCEPTED SUPPLEMENTAL NEW DRUG APPLICATION FOR TYVYT PLUS BEVACIZUMAB BIOSIMILAR INJECTION AND CHEMOTHERAPY.Further company coverage: 1801.HK. ((reuters.briefs@thomsonreuters.com;)).

Innovent Biologics Says PD-1 Inhibitor Tyvyt Successfully Included In Updated NDRL

Dec 3 (Reuters) - Innovent Biologics Inc <1801.HK>::PD-1 INHIBITOR TYVYT (SINTILIMAB INJECTION) SUCCESSFULLY INCLUDED IN UPDATED NATIONAL REIMBURSEMENT DRUG LIST.Further company coverage: 1801.HK. ((Reuters.Briefs@thomsonreuters.com;)).

Innovent Biologics Says NMPA Approved Novel Drug Olverembatinib To Treat Chronic Myeloid Leukemia

Nov 26 (Reuters) - Innovent Biologics Inc <1801.HK>::NMPA APPROVES NOVEL DRUG OLVEREMBATINIB FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA.

Innovent Biologics Says NMPA Accepted Supplemental NDA For TYVYT

Sept 23 (Reuters) - Innovent Biologics Inc <1801.HK>::NMPA ACCEPTED SUPPLEMENTAL NDA FOR TYVYT (SINTILIMAB INJECTION) IN COMBINATION WITH CHEMOTHERAPY.

Innovent Biologics Says Co And Genfleet Therapeutics (Shanghai) Inc Entered Into Exclusive Global License Agreement

Sept 2 (Reuters) - Innovent Biologics Inc <1801.HK>::CO AND GENFLEET THERAPEUTICS (SHANGHAI) INC. ENTERED INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT.GENFLEET WILL RECEIVE AN UPFRONT PAYMENT OF US$22 MILLION AT SIGNING.AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION RIGHTS OF GENFLEET'S LEAD KRAS G12C INHIBITOR CANDIDATE, GFH925 IN CHINA.

Innovent Biologics To Collaborate With Bolt Biotherapeutics

Aug 27 (Reuters) - Innovent Biologics Inc <1801.HK>::CO AND BOLT BIOTHERAPEUTICS TO COLLABORATE TO DEVELOP 3 NEW ONCOLOGY BOLTBODY ISAC PROGRAMS.UNDER AGREEMENT, CO HAS RIGHTS TO ALL 3 PROGRAMS IN CHINA, AND RETAINS OPTION TO LICENSE GLOBAL RIGHTS FOR 1 PROGRAM.BOLT WILL RECEIVE UPFRONT PAYMENT OF $5 MILLION IN CASH FROM CO AT SIGNING AND POSSIBLE FUTURE EQUITY INVESTMENT OF UP TO $10 MILLION.

Bolt Biotherapeutics And Innovent Biologics Announce Collaboration

Aug 26 (Reuters) - Bolt Biotherapeutics Inc <BOLT.O>::BOLT BIOTHERAPEUTICS INC -.BOLT BIOTHERAPEUTICS AND INNOVENT BIOLOGICS ANNOUNCE COLLABORATION TO DEVELOP THREE NEW ONCOLOGY BOLTBODY™ ISAC PROGRAMS.BOLT BIOTHERAPEUTICS INC - INNOVENT WILL PAY BOLT AN UPFRONT PAYMENT AND FUND DEVELOPMENT THROUGH CLINICAL PROOF OF CONCEPT.BOLT BIOTHERAPEUTICS INC - INNOVENT HAS RIGHTS TO ALL PROGRAMS IN GREATER CHINA.BOLT BIOTHERAPEUTICS INC - BOTH PARTIES HAVE OPTIONS TO PARTICIPATE IN FULL DEVELOPMENT AND COMMERCIALIZATION FOR VARIOUS REGIONS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up